Gene · 8793
Papers1,762
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 1,762
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dental Pulp Stem Cell Heterogeneity: Finding Superior Quality "Needles" in a Dental Pulpal "Haystack" for Regenerative Medicine-Based Applications. | Stem Cells Int | 2022 | 35027930 | PubTator, text mining | PubMed |
| Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance. | Cell Commun Signal | 2022 | 35000592 | PubTator, text mining | PubMed |
| Anticancer effects of picrasidine I on oral squamous cell carcinoma. | Environ Toxicol | 2022 | 34894061 | PubTator, text mining | PubMed |
| Roles of antiviral sensing and type I interferon signaling in the restriction of SARS-CoV-2 replication. | iScience | 2022 | 34877479 | PubTator, text mining | PubMed |
| Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist. | Cancer Lett | 2022 | 34728311 | PubTator, text mining | PubMed |
| Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma. | Transl Oncol | 2022 | 34649148 | PubTator, text mining | PubMed |
| Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases. | Heart Fail Rev | 2022 | 34313900 | PubTator, text mining | PubMed |
| Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development. | Curr Neuropharmacol | 2022 | 33998995 | PubTator, text mining | PubMed |
| Molecular and cellular paradigms of multidrug resistance in cancer. | Cancer Rep (Hoboken) | 2022 | 33052041 | PubTator, text mining | PubMed |
| Sex Differences in Molecular Mechanisms of Cardiovascular Aging. | Front Aging | 2021 | 35822017 | PubTator, text mining | PubMed |
| Network pharmacology-based analysis for unraveling potential cancer-related molecular targets of Egyptian propolis phytoconstituents accompanied with molecular docking and in vitro studies. | RSC Adv | 2021 | 35423607 | PubTator, text mining | PubMed |
| Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non-Small Cell Lung Cancer. | Front Genet | 2021 | 35186013 | PubTator, text mining | PubMed |
| CD26 Inhibition Potentiates the Therapeutic Effects of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells by Delaying Cellular Senescence. | Front Cell Dev Biol | 2021 | 35178399 | PubTator, text mining | PubMed |
| Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics. | Front Cell Dev Biol | 2021 | 35096828 | PubTator, text mining | PubMed |
| Shaping the Innate Immune Response Through Post-Transcriptional Regulation of Gene Expression Mediated by RNA-Binding Proteins. | Front Immunol | 2021 | 35087521 | PubTator, text mining | PubMed |
| TRAIL Triggers CRAC-Dependent Calcium Influx and Apoptosis through the Recruitment of Autophagy Proteins to Death-Inducing Signaling Complex. | Cells | 2021 | 35011619 | PubTator, text mining | PubMed |
| Optimized Attenuated Salmonella Typhimurium Suppressed Tumor Growth and Improved Survival in Mice. | Front Microbiol | 2021 | 35003007 | PubTator, text mining | PubMed |
| Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer. | Front Oncol | 2021 | 34976832 | PubTator, text mining | PubMed |
| Integral Analyses of Competing Endogenous RNA Mechanisms and DNA Methylation Reveal Regulatory Mechanisms in Osteosarcoma. | Front Cell Dev Biol | 2021 | 34957096 | PubTator, text mining | PubMed |
| Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma. | Molecules | 2021 | 34946664 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8793/papers?page=13